These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32808600)

  • 1. Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients.
    Zhu L; Cui Q; Liu Y; Liu Z; Zhang Y; Liu F; Wang J
    Med Sci Monit; 2020 Aug; 26():e925114. PubMed ID: 32808600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome.
    Zhu L; Liu Y; Zhang W; Zhang Z; Zhou L; Zhang H; Zhang Y; Liu F; Liu P; Liu Z; Wang J
    J Int Med Res; 2020 Nov; 48(11):300060520965848. PubMed ID: 33138662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.
    Tenenbaum A; Medvedofsky D; Fisman EZ; Bubyr L; Matetzky S; Tanne D; Klempfner R; Shemesh J; Goldenberg I
    PLoS One; 2012; 7(4):e35298. PubMed ID: 22523582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Events After Discontinuation of β-Blockers in Patients Without Heart Failure Optimally Treated After Acute Myocardial Infarction: A Cohort Study on the French Healthcare Databases.
    Neumann A; Maura G; Weill A; Alla F; Danchin N
    Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004356. PubMed ID: 29653999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes.
    Xie G; Sun Y; Myint PK; Patel A; Yang X; Li M; Li X; Wu T; Li S; Gao R; Wu Y
    Lipids Health Dis; 2017 Aug; 16(1):155. PubMed ID: 28810873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome.
    Turner RM; Yin P; Hanson A; FitzGerald R; Morris AP; Stables RH; Jorgensen AL; Pirmohamed M
    J Clin Lipidol; 2017; 11(1):204-214. PubMed ID: 28391887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe-Statin Combination Therapy.
    Nußbaumer B; Glechner A; Kaminski-Hartenthaler A; Mahlknecht P; Gartlehner G
    Dtsch Arztebl Int; 2016 Jul; 113(26):445-53. PubMed ID: 27412989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-blocker dosage and outcomes after acute coronary syndrome.
    Allen JE; Knight S; McCubrey RO; Bair T; Muhlestein JB; Goldberger JJ; Anderson JL
    Am Heart J; 2017 Feb; 184():26-36. PubMed ID: 27892884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
    Al-Zakwani I; Zubaid M; Alsheikh-Ali AA; Almahmeed W; Rashed W
    Cardiovasc Ther; 2018 Dec; 36(6):e12463. PubMed ID: 30079461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Ojeifo O; Wiviott SD; Antman EM; Murphy SA; Udell JA; Bates ER; Mega JL; Sabatine MS; O'Donoghue ML
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1275-81. PubMed ID: 24239201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study.
    Iannaccone M; D Ascenzo F; De Filippo O; Gagliardi M; Southern DA; Raposeiras-Roubín S; Abu-Assi E; Henriques JPS; Saucedo J; González-Juanatey JR; Wilton SB; Kikkert WJ; Nuñez-Gil I; Ariza-Sole A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Huczek Z; Nie SP; Fujii T; Correia L; Kawashiri MA; García-Acuña JM; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Kowara M; Filipiak K; Wang X; Yan Y; Fan JY; Ikari Y; Nakahashi T; Sakata K; Yamagishi M; Moretti C; Gaita F; Kalpak O; Kedev S
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):61-71. PubMed ID: 27738920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II.
    Krum H; Bailey M; Meyer W; Verkenne P; Dargie H; Lechat P; Anker S
    Cardiology; 2007; 108(1):28-34. PubMed ID: 16960445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of long-term use of evidence-based therapies after non-ST-segment elevation acute coronary syndrome. The S-Témoin survey.
    Danchin N; Diévart F; Thébaut JF; Grenier O; Mihci E; Herrmann MA; Ferrières J
    Int J Cardiol; 2009 Mar; 133(1):32-40. PubMed ID: 18375000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand.
    Wongsalap Y; Kengkla K; Poolpun D; Saokaew S
    J Cardiol; 2021 Jun; 77(6):669-676. PubMed ID: 33455848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study.
    Pereira M; Araújo C; Dias P; Lunet N; Subirana I; Marrugat J; Capewell S; Bennett K; Azevedo A
    Eur J Prev Cardiol; 2014 Nov; 21(11):1401-8. PubMed ID: 23787795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription of statins at discharge and 1-year risk of major clinical outcomes among acute coronary syndromes patients with extremely low LDL-cholesterol in clinical pathways for acute coronary syndromes studies.
    Sun Y; Xie G; Patel A; Li S; Zhao W; Yang X; Wu T; Li M; Li X; Du X; Hu R; Huo Y; Hu D; Gao RL; Wu Y
    Clin Cardiol; 2018 Sep; 41(9):1192-1200. PubMed ID: 30084224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.